U. Dunzendorfer

发表

Clinical experience: symptomatic management of BPH with terazosin.

U. Dunzendorfer, 1988, Urology.

Transferrin, C3 complement, haptoglobin, plasminogen and alpha 2-microglobulin in patients with urogenital tumors.

K. Jung, U. Dunzendorfer, G. Ohlenschläger, 1980, European urology.

The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction — A rationale for a PDE5 inhibitor combination therapy

U. Dunzendorfer, Annette Dunzendorfer, A. Behm, 2004 .

Plasma lipid bound sialic acid in patients with prostate and bladder cancer.

W. Whitmore, C. Stock, A. Dnistrian, 1981, Investigative urology.

Polyamines, hydrolases (PAP, LAP, SDH, plasmin) TSH, T3, T4 and C-peptide in benign hyperplasia of the prostate

U. Dunzendorfer, D. Russell, W. Weber, 2004, Urological Research.

Efficacy of once‐A‐day terazosin in benign prostatic hyperplasia: A randomized, double‐blind placebo‐controlled clinical trial

U. Dunzendorfer, C. Maurath, P. G. Fabricius, 1990, The Prostate. Supplement.

Quantification of alpha-fetoprotein and beta-HCG in testis tumor patients.

U. Dunzendorfer, C. Jurincic, 1987, Urologia internationalis.

Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. I. Diagnostic value and use in battery of conventional tumor markers.

U. Dunzendorfer, J. Kellen, D. Drahovsky, 1981, Oncology.

LH, FSH, TSH, Prolactin, HCG and Prostaglandin F2α in Patients with Treated Testis Tumors *

U. Dunzendorfer, D. Drahovksy, H. Zahradnik, 2009 .

Antigrowth effect of some inhibitors of polyamine synthesis on transplantable prostate cancer.

W. Whitmore, U. Dunzendorfer, M. Baliś, 1983, Oncology.

Altered polyamine profiles in prostatic hyperplasia and in kidney tumors.

U. Dunzendorfer, D. Russell, 1978, Cancer research.

Synthesis and body distribution of alpha-aminoisobutyric acid-L-11C in normal and prostate cancer-bearing rat after chemotherapy

P. Conti, W. Whitmore, J. Dahl, 2004, European Journal of Nuclear Medicine.

The autonomic innervation of the human prostate

D. Jonas, U. Dunzendorfer, W. Weber, 1976, Urological Research.

Parathyroid hormone, cAMP, electrolytes and uric acid after high dose CaCl2 in patients with idiopathic stone formation.

U. Dunzendorfer, H. Schmidt‐Gayk, 1981, Endokrinologie.

New Results on the Pharmacokinetics of Fosfestrol

U. Dunzendorfer, H. Oelschläger, D. Rothley, 1988 .

C-peptide, testosterone, estrogen, cortisol and zinc in patients with benign hyperplasia of the prostate.

U. Dunzendorfer, D. Drahovsky, 1980, Urologia internationalis.

Chemotherapy and trace element levels in blood and tissue of rats implanted with prostate tumor cells

W. Whitmore, G. Schrauzer, U. Dunzendorfer, 1985, Biological Trace Element Research.

Some effects of inhibitors of polyamine synthesis on experimental prostatic cancer.

W. Whitmore, U. Dunzendorfer, M. Baliś, 1984, Arzneimittel-Forschung.

Na‐Tartrate in the Treatment of Chronic Nonbacterial Prostatitis

U. Dunzendorfer, R. Milbradt, H. Feller, 2009, Andrologia.

Experimental Chemotherapy in a Transplantable Renal Adenocarcinoma

W. Whitmore, U. Dunzendorfer, E. Kleinert, 1983 .

Diethylstilbestrol-Diphosphate, Fosfestrol ‘Reevaluated’

U. Dunzendorfer, 1988 .

[Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma. An experimental and clinical study].

U. Dunzendorfer, M. Knöner, 1985, Onkologie.

Testosterone, LH and FSH in Patients with Treated Testicular Carcinomas

U. Dunzendorfer, W. W. A. F. Urologie, FrankfurtM J.-W.-G. Universität, 1978, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Drug combinations in the therapy of low response to phosphodiesterase 5 inhibitors in patients with erectile dysfunction.

U. Dunzendorfer, Annette Dunzendorfer, A. Behm, 2002, In vivo.